Mark Merchant
Impact in
- Oncology top 1%
- Cancer Cells and Metastasis
- Hepatology top 2%
- Liver physiology and pathology
Papers in
-
- Melanoma and MAPK Pathways 14
- PI3K/AKT/mTOR signaling in cancer 5
- Epigenetics and DNA Methylation 4
- Protein Degradation and Inhibitors 4
- Oncology 21
- Viral-associated cancers and disorders 6
- Colorectal Cancer Treatments and Studies 4
- Co-authors
- Jeff Settleman (6 shared papers)Richard Longnecker (7 shared papers)Timothy R. Wilson (2 shared papers)Hartmut Koeppen (3 shared papers)Robert D. Dredge (3 shared papers)Yibing Yan (4 shared papers)Emily Chan (7 shared papers)Eric S. Lander (2 shared papers)
- Journals
- Cancer Research (10 papers)Molecular Cancer Therapeutics (7 papers)Clinical Cancer Research (3 papers)Proceedings of the National Academy of Sciences (2 papers)Molecular and Cellular Biology (2 papers)
- Partner nations
- United StatesFranceGermany
In The Last Decade
Mark Merchant
63 papers receiving 4.8k citations
Mark Merchant's Hit Papers
Peers
Comparison fields: 5 of 117
- Oncology 1.5k
- Hepatology 396
- Molecular Biology 2.9k
- Cancer Research 534
- Pathology and Forensic Medicine 509
Countries citing papers authored by Mark Merchant
This map shows the geographic impact of Mark Merchant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Merchant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Merchant more than expected).
Fields of papers citing papers by Mark Merchant
This network shows the impact of papers produced by Mark Merchant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Merchant. The network helps show where Mark Merchant may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Merchant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 66 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors Hit paper breakdown → | 2012 | 889 |
| 2 | 1994 | 485 | |
| 3 | 2013 | 259 | |
| 4 | 2006 | 243 | |
| 5 | 2018 | 232 | |
| 6 | 2014 | 230 | |
| 7 | 1995 | 225 | |
| 8 | 2011 | 200 | |
| 9 | 2008 | 171 | |
| 10 | 2013 | 151 | |
| 11 | 2013 | 120 | |
| 12 | 2017 | 109 | |
| 13 | 2000 | 107 | |
| 14 | 2004 | 100 | |
| 15 | 2005 | 98 | |
| 16 | 1999 | 97 | |
| 17 | 2012 | 74 | |
| 18 | 2015 | 70 | |
| 19 | 2012 | 68 | |
| 20 | 2020 | 66 |
About Mark Merchant
Mark Merchant is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Hepatology and Immunology, having authored 66 papers that have together received 4.9k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (14 papers), Liver physiology and pathology (10 papers), Viral-associated cancers and disorders (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Epigenetics and DNA Methylation (4 papers), Protein Degradation and Inhibitors (4 papers) and Lung Cancer Treatments and Mutations (4 papers). The work is most often cited by research in Oncology (1.5k citations), Hepatology (396 citations), Molecular Biology (2.9k citations), Cancer Research (534 citations) and Pathology and Forensic Medicine (509 citations). Mark Merchant has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Jeff Settleman, Richard Longnecker, Timothy R. Wilson, Hartmut Koeppen, Robert D. Dredge, Yibing Yan, Emily Chan, Eric S. Lander, John G. Moffat and Eva Lin. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Clinical Cancer Research, Proceedings of the National Academy of Sciences and Molecular and Cellular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.